An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Amlodipine; Telmisartan

Criteria

Inclusion Criteria:

1. Patients with essential hypertension

2. Outpatient

Exclusion Criteria:

• Patients whose SBP >=180 mmHg or DBP >=110 mmHg at the end of treatment visit of the double-blind treatment period in the "non-responder trials"

• Patients who have met any of the exclusion criteria defined in the "non-responder trials"